PMID- 23957716
OWN - NLM
STAT- MEDLINE
DCOM- 20140821
LR  - 20220311
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 53
IP  - 1
DP  - 2014 Jan
TI  - Safety and efficacy of aerobic training in operable breast cancer patients 
      receiving neoadjuvant chemotherapy: a phase II randomized trial.
PG  - 65-74
LID - 10.3109/0284186X.2013.781673 [doi]
AB  - BACKGROUND: To evaluate the safety and efficacy of moderate-to-high intensity 
      aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
      METHODS: Twenty patients with stage IIB-IIIC operable breast cancer were randomly 
      assigned to receive doxorubicin plus cyclophosphamide (AC) or AC in combination 
      with aerobic training (AC + AET) (n = 10/group) for 12 weeks. The AC+ AET group 
      performed three supervised aerobic cycle ergometry sessions per week at 60%-100% 
      of exercise capacity (VO2peak). Safety outcomes included exercise testing as well 
      as treatment- and exercise training-related adverse events (AEs), whereas 
      efficacy outcomes included cardiopulmonary function and patient-reported outcomes 
      (PROs) as measured by a cardiopulmonary exercise test (CPET) and Functional 
      Assessment of Cancer Therapy-Breast (FACT-B) scale. RESULTS: Twelve 
      non-significant ECG abnormalities and three non-life threatening events occurred 
      during CPET procedures. One AE was reported during aerobic training. There were 
      no significant between group differences for clinician-documented events (e.g. 
      pain, nausea) or hematological parameters (p's > 0.05). Attendance and adherence 
      rates to aerobic training were 82% and 66%, respectively. Intention-to-treat 
      analysis indicated that VO2peak increased by 2.6 +/- 3.5 ml/kg/min (+ 13.3%) in the 
      AC + AET group and decreased by 1.5 +/- 2.2 ml/kg/min (-8.6%) in the AC group 
      (between group difference, p = 0.001). FACT-B increased 11.1 points in the AC + 
      AET group compared to a 1.5 point decrease in the AC group (between group 
      difference, p = 0.685). CONCLUSION: Moderate-to-high intensity aerobic training 
      when conducted with one-on-one supervision is a safe adjunct therapy associated 
      with improvements in cardiopulmonary function and select PROs during neoadjuvant 
      chemotherapy.
FAU - Hornsby, Whitney E
AU  - Hornsby WE
AD  - Duke University Medical Center , Durham, North Carolina , USA.
FAU - Douglas, Pamela S
AU  - Douglas PS
FAU - West, Miranda J
AU  - West MJ
FAU - Kenjale, Aarti A
AU  - Kenjale AA
FAU - Lane, Amy R
AU  - Lane AR
FAU - Schwitzer, Emily R
AU  - Schwitzer ER
FAU - Ray, Kaitlin A
AU  - Ray KA
FAU - Herndon, James E 2nd
AU  - Herndon JE 2nd
FAU - Coan, April
AU  - Coan A
FAU - Gutierrez, Antonio
AU  - Gutierrez A
FAU - Hornsby, Kyle P
AU  - Hornsby KP
FAU - Hamilton, Erika
AU  - Hamilton E
FAU - Wilke, Lee G
AU  - Wilke LG
FAU - Kimmick, Gretchen G
AU  - Kimmick GG
FAU - Peppercorn, Jeffrey M
AU  - Peppercorn JM
FAU - Jones, Lee W
AU  - Jones LW
LA  - eng
GR  - CA133895/CA/NCI NIH HHS/United States
GR  - CA138634/CA/NCI NIH HHS/United States
GR  - CA142566/CA/NCI NIH HHS/United States
GR  - CA143254/CA/NCI NIH HHS/United States
GR  - CA164751/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130819
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/pathology/*therapy
MH  - Carcinoma, Ductal, Breast/pathology/*therapy
MH  - Carcinoma, Lobular/pathology/*therapy
MH  - Chemotherapy, Adjuvant
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Exercise Test
MH  - *Exercise Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Safety
EDAT- 2013/08/21 06:00
MHDA- 2014/08/22 06:00
CRDT- 2013/08/21 06:00
PHST- 2013/08/21 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/08/22 06:00 [medline]
AID - 10.3109/0284186X.2013.781673 [doi]
PST - ppublish
SO  - Acta Oncol. 2014 Jan;53(1):65-74. doi: 10.3109/0284186X.2013.781673. Epub 2013 
      Aug 19.